Table 3.
Best overall response in relapsed/refractory indolent B-cell lymphoma and DLBCL for single-agent pinatuzumab vedotin
| Indolent B-cell lymphomaa | DLBCL | CLL | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||
| <1.8 mg/kg (n = 8) | 1.8 mg/kg (n = 3) | 2.4 mg/kg (n = 14) | <1.8 mg/kg (n = 8) | 1.8 mg/kg (n = 4) | 2.4 mg/kg (n = 25) | 3.2 mg/kg (n = 1) | <1.8 mg/kg (n = 6) | 1.8 mg/kg (n = 3) | 2.4 mg/kg (n = 1) | |
| Complete response | 0 | 0 | 3 (21.4%) | 2 (25.0%) | 1 (25.0%) | 4 (16.0%) | 0 | 0 | 0 | 0 |
| Partial response | 0 | 1 (33.3%) | 4 (28.6%) | 1 (12.5%) | 1 (25.0%) | 5 (20.0%) | 1 (50.0%) | 0 | 0 | 0 |
| Stable disease | 4 (50.0%) | 2 (66.7%) | 2 (14.3%) | 1 (12.5%) | 0 (0.0%) | 4 (16.0%) | 0 | 1 (16.7%) | 1 (33.3%) | 0 |
| Progressive disease | 4 (50.0%) | (0.0%) | 3 (21.4%) | 4 (50.0%) | 1 (25.0%) | 11 (44.0%) | 0 | 2 (33.3%) | 2 (66.7%) | 0 |
| Unable to evaluateb | 0 | 0 | 0 | 0 | 0 | 1(4.0%) | 0 | 0 | 0 | 0 |
| Missingc | 0 | 0 | 2 (14.3%) | 0 | 1 (25.0%) | 0 | 0 | 3 (50.0%) | 0 | 1 (100.0%) |
a
Includes follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma. No patients with indolent B-cell lymphoma received pinatuzumab vedotin at 1.8 mg/kg.
b
Scan was done but response could not be determined.
c
Early discontinuation prior to scheduled tumor assessment or assessment visit was not reached at the time of data cutoff.